Oncophage: Step to the future for vaccine therapy in melanoma

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1973-1984

  di Pietro, Alessandra ^a   Tosti, Giulio ^a   Ferrucci, Pier F ^a   Testori, Alessandro ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

HSPPCs; HSPs; Metastatic melanoma; Oncophage; Vitespen

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; C 100 02; C 100 06; C 100 21; CARBOPLATIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DOCETAXEL; ELESCLOMOL; FOTEMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELANOMA VACCINE; PACLITAXEL; PEPTIDE VACCINE; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; VITESPEN;

ADJUVANT THERAPY; ARTICLE; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; RIGOR; THYROID DISEASE; VERTIGO; VOMITING;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERONS; MELANOMA; ONCOLYTIC VIROTHERAPY;

EID: 57649220640     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802517970     Document Type: Article

References (73)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
2. Lewis JJ. Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci USA 2004;101(Suppl 2):14653-6
3. Srivastava PK, Das MR. The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen. Int J Cancer 1984;33(3):417-22
4. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986;83(10):3407-11
5. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994;6:728-32
6. Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-8
7. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36
8. Balch C, Kirkwood J, Reintgen DS. Cutaneous melanoma. In: Devita VT, editor. Cancer: principles and practice of oncology, 5th edition. Philadelphia: Lippincott, 1997. p. 1947-94
9. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
10. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001-7
11. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
12. Gogas H, Bafaloukos D, Bedikian AY. The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 2004;14:415-20
13. Gehrmann M. Drug evaluation: STA-4783 - enhancing taxane efficacy by induction of Hsp70. Curr Opin Investig Drugs 2006;7:574-80
14. Al Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1982;66:31-5
15. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987;5:574-8
16. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997;9:205-13
17. Agarwala SS, Ferri W, Gooding W, et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-84
18. Bajetta E, Di Leo A, Zanspino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-11
19. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51
20. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52
21. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-51
22. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88
23. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75
24. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2083-90
25. Parmiani G, Castelli C, Santinami M, et al. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19:121-7
26. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7
27. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77
28. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16
29. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50
30. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
31. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
32. Whearley K, Ives NJ, Lorigan P. Does adjuvant vaccine therapy really have activity in malignant melanoma? J Clin Oncol 2007;25:4693-5
33. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007;25(Suppl 2):B4-16
34. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994;152:5398-403
35. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585-8
36. Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61:222-7
37. Nicchitta CV. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr Opin Immunol 1998;10:103-9
38. Sato K, Torimoto Y, Tamura Y, et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 2001;98:1852-7
39. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20
40. Wang XY, Kazim L, Repasky EA, et al. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001;166:490-7
41. Yedavelli SP, Guo L, Daou ME, et al. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 1999;4:243-8
42. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169(10):5424-32
43. Basu S, Binder RJ, Ramalingam T, et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13
44. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for hear shock protein gp96. Nat Immunol 2000;1:151-5
45. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42
46. Berwin B, Hart JP, Pizzo SV, et al. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J Immunol 2002;168:4282-6
47. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-12
48. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005;7(2):104-8
49. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 2004;101:6128-33
50. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 2003;278(1):174-9
51. Dybahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105(6):685-90
52. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277(17):15028-34
53. Srivastava PK, Jaikaria NS. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol Biol 2001;56:75-86
54. Gordon NF, Clark BL. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 2004;32:63-9
55. Available from: http://www.antigenics.com
56. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80
57. Eton O. Autologous tumor-derived heat-shock-protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Proc Am Assoc Cancer Res AACR 2000. San Francisco, California, USA 2000;41 [Abstract 3463]
58. Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006;55:958-68
59. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26:955-62
60. Heike M. Pilot trial of vaccination with autologous tumour-derived Gp96 Heat Shock Protein-Peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. ASCO 2000;19
61. Hertkorn C, Lehr A, Woefel T. Phase I trial of vaccination with autologous tumour derived gp96 (Oncophage) in patients after surgery for gastric cancer. ASCO 2002;21
62. Amato R. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumour derived Heat Shock Protein-peptide complex-96 (HSPP-96). ASCO 1999;18
63. Amato R. Patients with renal cell carcinoma (RCC) using autologous tumour-derived Heat Shock Protein-Peptide Complex (HSPPC-96) with or without Interleukin-2 (IL-2). ASCO 2000;19
64. Assikis VJ, Daliani D, Pagliaro L. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). ASCO 2003;22
65. Wood CG, Escudier B, Gorelov S. A multicenter randomized study of adjuvant Heat Shock Protein-Peptide Complex-96 (HSPPC-96) vaccine in patients with high risk of recurrence after nephrectomy for renal call carcinoma (RCC)-A preliminary report. ASCO 2004;23
66. Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007;52:1964-72
67. Dong J, Wei J. Effective vaccines of autologous cancer-derived Heat Shock Protein gp70-complexes in patients with cancer malignancies (pancreatic carcinoma, colorectal cancer). ASCO 2005
68. Younes A. A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:183-5
69. Younes A, Fayad LE, Pro B. Safety and efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) in low-grade lymphoma. ASCO 2003;22
70. Oki Y, McLaughlin P, Fayad LE, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007;109:77-83
71. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45
72. Li Z. Autologous leukocyte-derived Heat Shock Protein 70-peptide complex as a vaccine for chronic myelogeneous leukemia in chronic phase: An updated phase I study. Blood 2003;102:11
73. Li Z, Nash JD, Qiao Y. An autologous tumour-derived heat shock protein vaccine for high risk ovarian cancer. ASCO 2005